| Population name | Pehlivan |
| Genome | not specified |
| Consortium | University of Istanbul |
| Super population | SAS |
| Population description | Patients diagnosed with COVID-19 between April and June 2020 who were admitted to the COVID-19 center of a university hospital, and 100 healthy individuals without any known were included as controls. Healthy controls consisted of individuals who were negative for Sars-CoV-2 antibody (Sars-Cov-2 IgM, IgG) and were negative in two PCR results taken with an interval of 48 hours. Patients included those that were diagnosed with COVID-19 who show false negativity with initial examinations before hos |
| Population origin | Istanbul, Turkey |
| Case population size | 70 |
| Control population size | 100 |
| Comorbidities | not specified |
| Mean / median age | not specified |
| Sex | not specified |
| Severity | Susceptibility |
| Sample source | Nasopharyngeal and Clinical characteristics |
| Method | PCR and/or RFLP was used to isolate DNA samples from blood leukocytes at the time of diagnosis. MBL2-rs1800450, NOS3-rs1799983 and NOS3-intron 4 VNTR gene polymorphisms were analyzed. |
| Bioinformatics | Logistic regression was used to analyse statistical differences analysis between groups. The adjusted odds ratios (ORs) were calculated with a logistic regression model that checked for sex and age and are reported with 95% confidence intervals (CIs). Differences between the patients’ group were compared using the chi-square test and the Fisher exact test when required. A p-value of less than 0.05 was accepted as significant. |
| Imputation details | NA |
| Limitations | a. Limited patient population, b. No MBL serum levels were recorded |